×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
REGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
10:27 am
regn
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3 [Yahoo! Finance]
Low
Report
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3 [Yahoo! Finance]
11/16
06:05 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/15
08:04 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
11/15
06:03 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
11/15
01:17 am
regn
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) [Yahoo! Finance]
Low
Report
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) [Yahoo! Finance]
11/15
12:59 am
regn
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Low
Report
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
11/14
08:09 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.
11/13
11:16 am
regn
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease [Yahoo! Finance]
Low
Report
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
-9.3%
regeneron pharmaceuticals, inc.
8/1/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
-0.2%
regeneron pharmaceuticals, inc.
5/2/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
7.0%
regeneron pharmaceuticals, inc.
2/2/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
-3.5%
regeneron pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
04:04 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Nov 08 Filed by: MURPHY ANDREW J
Low
Report
Form 4 REGENERON PHARMACEUTICAL For: Nov 08 Filed by: MURPHY ANDREW J
11/5
04:23 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Nov 01 Filed by: McCourt Marion
Low
Report
Form 4 REGENERON PHARMACEUTICAL For: Nov 01 Filed by: McCourt Marion
11/1
04:38 pm
regn
Form 144 REGENERON PHARMACEUTICAL Filed by: McCourt Marion
Low
Report
Form 144 REGENERON PHARMACEUTICAL Filed by: McCourt Marion
10/31
04:34 pm
regn
Form S-3ASR REGENERON PHARMACEUTICAL
Low
Report
Form S-3ASR REGENERON PHARMACEUTICAL
10/31
07:17 am
regn
Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30
Medium
Report
Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30
10/31
07:11 am
regn
Form 8-K REGENERON PHARMACEUTICAL For: Oct 31
Medium
Report
Form 8-K REGENERON PHARMACEUTICAL For: Oct 31
10/7
07:00 am
regn
Form 8-K REGENERON PHARMACEUTICAL For: Oct 07
Low
Report
Form 8-K REGENERON PHARMACEUTICAL For: Oct 07
10/3
04:02 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Oct 01 Filed by: McCourt Marion
Low
Report
Form 4 REGENERON PHARMACEUTICAL For: Oct 01 Filed by: McCourt Marion
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
7.4%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
TOP News Decliners
3/19
Coronavirus Proves Drug Companies To Be Innovators [Forbes]
-10.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: